Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate in the following conferences in March.

• The TD Cowen 44th Annual Healthcare Conference in Boston, MA
  • Panel Discussion: Orphan Epilepsies - March 6 at 10:30 a.m. E.T.

• Leerink Partners 2024 Global Biopharma Conference in Miami, FL
  • Presentation - March 11 at 4:00 p.m. E.T.

Links to the events can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221704060/en/

Investors
Jim DeNike
Senior Director, Investor Relations
Marinus Pharmaceuticals, Inc.
[email protected]

Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
[email protected]

Source: Marinus Pharmaceuticals

You May Also Be Interested In

• Alibaba Group Announced Pricing of HK$80 Billion Placing of New Shares in Hong Kong
• New Construction Is Booming in Las Vegas, and Garage Door Choices Are Changing With It
• Top Meme Coin To Buy: Pipedog Selling Persists Despite 3,294% APY as AlphaPepe Stage 20 Keeps Filling